0
0
US President Donald Trump announced a plan to impose escalating tariffs on imported pharmaceuticals as part of an effort to bring drug manufacturing back to the United States. In a CNBC interview on August 5, 2025, Trump said the tariffs would begin at a relatively low level but would increase to 150 percent within a year to 18 months and ultimately reach as high as 250 percent. He emphasized the goal of encouraging pharmaceutical production domestically.
Additionally, Trump revealed plans to levy tariffs on foreign semiconductors and chips in the near future, though he provided no specific details. These tariff threats are part of a broader campaign pushing major drug suppliers to significantly reduce costs or face further actions.
The announcement comes amid escalating trade tensions between the US and India. Trump stated he would substantially raise tariffs on Indian goods, revising a previous 25 percent rate upward, accusing India of purchasing large quantities of Russian oil and reselling it for profit, thereby allegedly supporting Moscow’s war effort. India dismissed these allegations as “unjustified and unreasonable” and pledged to safeguard its national interests and economic security. Russia criticized Trump’s remarks as “illegitimate” and supported India’s sovereign right to choose trade partners.
This move has elicited concerns about its impact on global pharmaceutical supply chains and bilateral trade relations, particularly between the US and India. The US administration’s push to repatriate manufacturing through punitive tariffs represents a significant shift in trade policy with potential wide-ranging effects on international markets.
Disclaimer: This article is based on statements made by US President Donald Trump and related official remarks as of August 5, 2025. The information reflects announced intentions and political positions which may be subject to change. The views expressed do not represent the official positions of involved governments or organizations beyond the cited statements.
